Preparing for the Next Pandemic
A new research center led by Richard Plemper in the Institute for Biomedical Sciences will develop critical antiviral drugs to meet the challenge of existing and newly evolving threats, such as coronaviruses.
A new antiviral drug tested in the Institute for Biomedical Sciences at Georgia State against influenza virus and SARS-CoV-2 has been recommended for emergency use authorization to treat COVID-19 in the United States by pharmaceutical companies that completed a Phase 3 clinical trial and achieved promising results.
Professor Christopher Basler has received two grants from the National Institutes of Health to study two coronaviruses that cause human disease: Middle East respiratory syndrome (MERS) coronavirus and SARS-CoV-2.
The Center for Translational Antiviral Research has been established in the Institute for Biomedical Sciences at Georgia State University to fill the gap for developing affordable, much-needed antiviral drugs that will reduce severe viral diseases and meet the threats imposed by existing and newly evolving viruses.
Scientists in the Institute for Biomedical Sciences have shed light on how cells can slow replication of the Ebola virus, preventing infection. “We hope these findings will enable us to develop new ways to prevent or treat Ebola.”
Compounds targeting two key enzymes are potent inhibitors of SARS-CoV-2, the virus that causes COVID-19, according to a study led by the Institute for Biomedical Sciences at Georgia State.
For the past five years, Regents’ Professor Binghe Wang and his collaborators have worked to design a safe way to deliver CO to human patients.
Dr. Sang-Moo Kang, professor in the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.7 million federal grant to study seasonal and universal vaccination in elderly populations with pre-existing immunity to influenza viruses.